Radiopharmaceutical Stem Cell Tracking for Neurological Diseases

Paulo Henrique Rosado-de-Castro,1,2 Pedro Moreno Pimentel-Coelho,2 Bianca Gutfilen,1 Sergio Augusto Lopes de Souza,1 Gabriel Rodriguez de Freitas,2,3 Rosalia Mendez-Otero,2 and Lea Mirian Barbosa da Fonseca1

1 Department of Radiology, School of Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
2 Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Avenida Carlos Chagas Filho 373, CCS, Bloco G, Cidade Universitária, Ilha do Fundão, 21941-590 Rio de Janeiro, RJ, Brazil
3 D’Or Institute for Research and Education, Rio de Janeiro, RJ, Brazil

Correspondence should be addressed to Paulo Henrique Rosado-de-Castro; phrosadodecastro@ufrj.br

Received 29 November 2013; Accepted 3 May 2014; Published 25 May 2014

Academic Editor: Gianluca Valentini

Copyright © 2014 Paulo Henrique Rosado-de-Castro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Although neurological ailments continue to be some of the main causes of disease burden in the world, current therapies such as pharmacological agents have limited potential in the restoration of neural functions. Cell therapies, firstly applied to treat different hematological diseases, are now being investigated in preclinical and clinical studies for neurological illnesses. However, the potential applications and mechanisms for such treatments are still poorly comprehended and are the focus of permanent research. In this setting, noninvasive in vivo imaging allows better understanding of several aspects of cell therapies. Amongst the various methods available, radioisotope cell labeling has become one of the most promising since it permits tracking of cells after injection by different routes to investigate their biodistribution. A significant increase in the number of studies utilizing this method has occurred in the last years. Here, we review the different radiopharmaceuticals, imaging techniques, and findings of the preclinical and clinical reports published up to now. Moreover, we discuss the limitations and future applications of radioisotope cell labeling in the field of cell transplantation for neurological diseases.

1. Introduction

In spite of the significant progress achieved in the medical field in the past decades, neurological illnesses remain as one of the leading causes of disease burden in the world [1, 2]. In the next years, with the progressive ageing of the population, the prevalence of these diseases and the expenses associated with them are expected to increase even more [2]. Contemporary treatments such as pharmacological agents are restricted in their potential to improve neurological function and are unable to promote restoration of lost neurons and other brain cells damaged in such diseases. Stem cell transplantation, initially developed more than 40 years ago to treat hematological malignant disorder, has more recently demonstrated promising results in different ailments, including autoimmune, cardiovascular, and neurological diseases [3, 4].

The use of noninvasive in vivo imaging to track the transplanted cells allows a better understanding of several aspects of cell therapies, including their biodistribution. In this scenario, radioisotope cell labeling, an already well-established nuclear medicine technique, has emerged as one of the most powerful tools. In the following sections, we will review the preclinical and clinical studies that used radiopharmaceutical stem cell tracking for neurological diseases and discuss important aspects in the area.
2. Radiopharmaceutical Cell Labeling

Radiopharmaceutical cell labeling has been used for decades to systemically monitor cells in nuclear medicine studies such as labeled leukocyte scintigraphy for detection of infectious and inflammatory diseases [5–7]. Technetium-99m (\(^{99m}\)Tc) is currently the most used radionuclide in the world and is imaged with conventional nuclear medicine techniques, that is, 2-dimensional planar scans or 3-dimensional single photon emission computed tomography (SPECT). Additionally, SPECT images may be fused with conventional computed tomography (CT), resulting in SPECT/CT images that allow attenuation correction and better localization of nuclear medicine findings, significantly improving both sensitivity and specificity [8]. \(^{99m}\)Tc has wider availability and lower cost than other radionuclides, and its 6-h half-life allows cell tracking for up to 24 h with good resolution and low radiation dose to the patient and to the labeled cells [5–7].

Another conventional nuclear medicine radiopharmaceutical indium-111-oxine (\(^{111}\)In-oxine) allows cell tracking for up to 96 h but results in lower resolution images and leads to higher radiation dose to the patient and to the labeled cells. In addition, different studies have indicated that Auger electrons of \(^{111}\)In-oxine labeling affect cellular integrity and lead to cytotoxicity of stem cells [9–12]. \(^{18}\)F-FDG, which has a 110-minute half-life, is the most commonly used radiopharmaceutical for positron emission tomography (PET) and allows cell labeling and tracking for a few hours. Unlike SPECT scans, which are less commonly acquired with hybrid CT equipment, PET is routinely made in scanners that allow PET/CT acquisition. Moreover, PET has a two- to threefold higher spatial resolution than SPECT (3–6 mm versus 10–15 mm) and allows quantification of standardized uptake values, which may be used to compare response to different therapies [13–15].

Stem cell tracking with SPECT and PET may be separated in two strategies: direct and indirect. Direct labeling is made by incubating stem cells with a radiotracer in vitro and subsequently transplanting them and can be done with radiopharmaceuticals such as \(^{99m}\)Tc-hexamethylpropyleneamine oxime (\(^{99m}\)Tc-HMPAO) or \(^{111}\)In-oxine for SPECT and \(^{18}\)F-FDG for PET. Indirect cell labeling may be carried out via reporter gene/probe systems, which has been subject to excellent reviews [16–18]. In brief, reporter gene/probe systems have traditionally been divided in three groups, according to the way that the protein product of the reporter gene interacts with the reporter probe and causes its accumulation on the surface or inside the cells [16–18]: (1) reporter genes that encode enzymes that phosphorylate specific reporter probes leading to their entrapment; (2) reporter genes that encode protein receptors which in their turn bind to specific reporter probes; and (3) reporter genes that encode cell membrane transporters that accelerate the accumulation of reporter probes in the cells. One example of a reporter gene/probe system is the herpes simplex virus type I thymidine kinase (HSV1-TK) reporter gene that catalyzes reactions leading to the entrapment of a probe such as iodine-131-2’-fluoro-2’-deoxy-5’-iodo-1β-D-arabinofuranosyluracil (\(^{131}\)I-FIAU) for SPECT.

3. Search Strategy

For this review, references were identified in MEDLINE databases using the terms “nuclear medicine,” “cell therapy,” “labeled,” “neurologic,” and “brain.” Only articles published in English were reviewed and no date restriction was made.

4. Published Preclinical Trials

We identified 17 published articles in English that used radiopharmaceuticals to track the biodistribution of transplanted cells in animal models of neurological diseases. Eight of these were performed in a model of transient middle cerebral artery occlusion (MCAO), 3 in traumatic brain injury, 3 in global brain ischemia, two in spinal cord lesion, and one in thermocoagulation focal brain ischemia. Seven studies used \(^{111}\)In-oxine, another 7 utilized \(^{99m}\)Tc or \(^{99m}\)Tc-HMPAO, two employed \(^{111}\)I-FIAU, and \(^{18}\)F-FDG was used in one (Table 1).

4.1. Spinal Cord Injury. De Haro et al. [19] investigated radiopharmaceutical cell tracking 3 months after compressive spinal cord injury at T6–T8 level in rats. They injected 6 × 10⁶ rat bone marrow derived mesenchymal stem cells (BM-MSCs) labeled with \(^{111}\)In-oxine by the tail vein or by intraleSIONal injection and performed whole-body planar imaging from 3 to 10 days. They found that intravenous injection of \(^{111}\)In-oxine labeled BM-MSCs led to biodistribution mainly to the spleen, liver, and kidneys, while the vertebral column showed faint migration and the spinal cord did not show any activity. Also, there was high activity in the tail, where the cells were injected. In contrast, when the \(^{111}\)In-oxine labeled cells were injected into the traumatic centromedullar cavity, there was a persistent homing into the lesion site, without any distribution to the rest of the organism in the 10-day imaging period.

Lo et al. [22] carried out the transplantation of mouse embryo-derived fibroblasts from lineage NIH3T3 in a rat model of compressive spinal cord injury at T10 level. These cells contained the HSV1-TK reporter gene. A total of 1 × 10⁶ cells labeled with \(^{131}\)I-FIAU were injected at the L1 level immediately after the spinal cord lesion and whole-body planar imaging was performed at 2, 24, and 48 h. After cell transplantation, uptake was observed in the injection site at all time points.

4.2. Traumatic Brain Injury. Yoon et al. [24] explored the migration of rat BM-MSCs labeled with \(^{111}\)In-oxine injected in rats subjected to traumatic brain injury and in sham-operated animals. A total of 1 × 10⁶ cells were injected in the tail vein 24 h after the lesion and whole-body planar imaging was performed 24 h later. The viability and proliferation of labeled BM-MSCs were assessed for 14 days.
## Table 1: Preclinical studies using radiopharmaceuticals for stem cell tracking in neurology.

| Study reference | Radiopharmaceutical | Model | Animals | Cell type | Route | Time from lesion (months) | Number of treated animals (number of controls) | Number of cells injected | Infusion volume, rate, and duration | Imaging time points |
|-----------------|---------------------|-------|---------|-----------|-------|--------------------------|-----------------------------------------------|-------------------------|------------------------------------|---------------------|
| de Haro et al., 2005 [19] | 111In-oxine | Spinal cord injury at T8-T10 | Wistar rats | Rat BM-MSCs | Tail vein or intraspinally | 3 | 20 (no controls) | 6×10⁶ | 0.1 or 1 mL | 3–10 days |
| Makinen et al., 2006 [20] | 111In-oxine | Transient MCAO (120 minutes) | Wistar rats | Human UCB-MNCs | Femoral vein | 24 h | 13 (controls not specified) | 6×10⁶ | 0.5 mL | 0 and 24 h |
| Lappalainen et al., 2008 [21] | 111In-oxine | Transient MCAO (120 minutes) | Wistar rats | Human ES-NPCs or rat HPCs | Common carotid artery or femoral vein | 24 h | 13 (controls not specified) | 0.5 mL | 0, 24, and 72 h |
| Lo et al., 2008 [22] | 131I-FIAU | Spinal cord injury at T10 | Long-Evans rats | Mouse embryo-derived fibroblasts | Spinal cord at L1 level | 0 h | 20 (no controls) | 6×10⁶ | 0.5 mL | 2, 24, and 48 h |
| Detante et al., 2009 [23] | 99mTc-HMPAO | Transient MCAO (90 minutes) | Sprague-Dawley rats | Human BM-MSCs | Saphenous vein | 7 days | 9 (9 controls) | 3.4±1.2×10⁶ | 1 mL | 2 and 20 h |
| Yoon et al., 2010 [24] | 111In-oxine | Traumatic brain injury | Sprague-Dawley rats | Rat BM-MSCs | Tail vein | 24 h | 3 (2 controls) | 1×10⁶ | 1 mL | 24 h |
| Park et al., 2011 [25] | 99mTc-HMPAO | Traumatic brain injury | Sprague-Dawley rats | Rat BM-MSCs | Tail vein | Notspecified | 14 (13 controls) | 1×10⁶ | 0.5 mL | 4 h |
| Vasconcelos-dos-Santos et al., 2012 [26] | 99mTc | Permanent thermocoagulation of pial blood vessels | Wistar rats | Human BM-MNCs | Common carotid artery or jugular vein | 24 h | 12 (8 controls) | 3×10⁷ | 0.5 mL | 2 and 24 h |
| Arbá et al., 2012 [27] | 111In-oxine | Transient MCAO (120 minutes) | Wistar rats | Human UTCs | Tail vein | 48 h | 13 (12 controls) | 3×10⁸ | 2 mL | 0, 1, and 3 days |
| Mitkari et al., 2013 [28] | 111In-oxine | Transient MCAO (90 minutes) | Wistar rats | Human BM-MSCs | External carotid artery | 24 h | 19 (controls not specified) | 0.5–1.1×10⁶ | 0.5 mL | 30 minutes and 24 h |
| Gubert et al., 2013 [29] | 99mTc | Permanent bilateral common carotid ligation | Lister hooded rats | Rat BM-MNCs | Tail vein | 24 h | 23 (no controls) | 2×10⁷ | 4 mL | 1 h |
| Goldmacher et al., 2013 [30] | 111In-oxine | Transient MCAO (120 minutes) | Sprague-Dawley rats | Rat BM-MSCs | Tail vein | 24 h | 3 (3 controls) | 5×10⁵ | 0.5 mL | Not specified |
| Makela et al., 2013 [31] | 99mTc-HMPAO | Transient MCAO (7 minutes) | Pigs | Pig BM-MNCs | Brachiocephalic trunk | 24 h | 10 (no controls) | 6–20×10⁶ | 0.4 mL | 1 h |
| Gao et al., 2013 [32] | 99mTc-HMPAO | Transient MCAO (60 minutes) | Sprague-Dawley rats | Human BM-MSCs | Common carotid artery | 24 or 72 h | 4 (4 controls) | 2×10⁸ | 0.1 mL | 2 h |
| Gao et al., 2013 [33] | 99mTc-HMPAO | Transient MCAO (60 minutes) | Sprague-Dawley rats | Rat BM-MSCs | Internal carotid artery | 24 h | 20 (4 controls) | 2×10⁸ | 0.1 mL | 2 h |
| Wu et al., 2013 [34] | 131I-FIAU | Transient MCAO (60 minutes) | Sprague-Dawley rats | Rat BM-MSCs | Intracerebral, intraventricular, carotid artery or tail vein | 24 h | 20 (4 controls) | 2×10⁸ | 0.5 mL | 2, 8, and 24 h |
| Manley et al., 2013 [35] | 18F-FDG | Traumatic brain injury | Sprague-Dawley rats | Human BM-MSCs and/or collagen scaffold | Intracerebral, intraventricular, carotid artery or tail vein | 24 h | 9 (MSCs); 9 (MSCs + collagen) | 3×10⁷ | 0.2 mL | 3, 6, and 12 h |

**Legend**: 111In-oxine: indium-111-oxine; 131I-FIAU: iodine-131-2-[1-β-D-arabinofuranosyl-5-iodouracil; 18F-FDG: fluorine-18-fluorodeoxyglucose; 99mTc: technetium-99m; 99mTc-HMPAO: technetium-99m-hexamethylpropyleneamineoxime; BM-DCs: bone marrow-derived dendritic cells; BM-MNCs: bone marrow mononuclear cells; BM-MSCs: bone marrow-derived mesenchymal stem cells; EPCs: endothelial progenitor cells; ES-NPCs: embryonic stem cell-derived neural progenitor cells; HPCs: hippocampal progenitor cells; HPMA-C: hematopoietic progenitor cell-derived progenitor cells; HPCs: hippocampal progenitor cells; UTCs: umbilical tissue-derived cells.
In the whole-body images, the majority of $^{111}$In-BM-MSC signal was detected in the liver and spleen. Uptake in the brain was higher in animals that suffered traumatic brain injury (1.4%) in comparison to sham-operated (0.5%) or normal rats (0.3%).

In another study by the same group, Park et al. [25] tracked $^{99m}$Tc-HMPAO-labeled rat BM-MSCs transplanted in rats with traumatic brain injury and in sham-operated animals. Approximately $1 \times 10^6$ cells were infused in the tail vein 24 h after the lesion. Whole-body images were made 4 h later and subsequently the animals were euthanized and tissue samples were collected for gamma well counting. The authors also performed cytometric evaluation to assess apoptotic or necrotic changes up to the 7th day after labeling. Gamma well counting indicated that homing to the liver, kidneys, lungs, and spleen was not different between traumatic brain injury (36.7%±6.9%, 16.1%±1.7%, 8.2%±0.7%, and 26±0.7%, resp.) and sham-operated rats (41.2%±6.7%, 17.4%±2.1%, 8.1%±0.9%, and 29±1.0%, resp.; all $P > 0.05$). In spite of that, brain signal in traumatic hemispheres was significantly higher than in contralateral hemispheres, and this did not occur in sham-operated animals. Notwithstanding, on whole-body images there was no significant uptake in the brains of traumatic animals or controls.

Guan et al. [35] performed the only study using $^{18}$F-FDG for stem cell labeling in a neurological disease. Rats submitted to traumatic brain injury received human BM-MSCs only or collagen scaffolds impregnated with human BM-MSCs. A total of $3 \times 10^6$ $^{18}$F-FDG labeled cells were used in each group and whole-body PET imaging was carried out at 3, 6, and 12 h after cell transplantation. At the end of the imaging experiments, rats were euthanized and tissue samples from the two cerebral hemispheres, cerebellum, heart, lungs, liver, spleen, and kidneys were obtained for gamma-well counting. In whole-body scans at 6 and 12 h, animals that received the collagen scaffolds with BM-MSCs showed higher uptake in the lesion cavity and lower uptake in the contralateral hemisphere and other organs in comparison with animals that received BM-MSCs only. Furthermore, this finding was confirmed in gamma-well counting at 12 h after transplantation.

4.3. Transient Middle Cerebral Artery Occlusion. Mäkinen et al. [20] evaluated the homing of human umbilical cord blood mononuclear cells labeled with $^{111}$In-oxine 24 h after 120 minutes of transient MCAO in rats, one of the most commonly used models of stroke. An infusion of $1–7 \times 10^6$ cells was carried out in the femoral vein and SPECT/CT imaging was performed after 30 minutes and 24 h. The authors found that accumulation was greater in the lungs at 30 minutes and at 24 h in the liver. Homing of $^{111}$In-labeled cells was also seen in the spleen and kidneys, but not in the brain. Immunohistochemistry for human nuclei showed the presence of few cells in the brain, mainly in the ipsilateral hemisphere close to blood vessels.

Lappalainen et al. [21] examined the biodistribution of human embryonic stem cell-derived neural progenitor cells or rat hippocampal progenitor cells after 120 minutes of transient MCAO in rats. An injection of $1 \times 10^6$ cells was made in the carotid artery or femoral vein 24 h after the lesion and SPECT/CT imaging was done at 0 and 24 h. After the last images, tissue samples from the liver, spleen, lungs, kidneys, and brain were analyzed in a gamma well counter. The authors found that intravenous infusion led to accumulation of transplanted cells mainly in the liver, spleen, and kidneys, respectively, with no visible uptake in the brain. On the other hand, after carotid artery injection a low uptake was seen in the brain, with the remaining uptake in the other internal organs. Furthermore, the authors estimated the detection sensitivity of SPECT/CT to be of about 1000 $^{111}$In-oxine labeled cells and that labeling did not influence cell viability.

Detante et al. [23] studied the migration of human BM-MSCs after 90 minutes of transient MCAO in rats and in a control group without cerebral ischemia. A mean of $3.4 \pm 1.2 \times 10^6$ cells were injected into the saphenous vein 7 days after the ischemia and planar imaging was performed after 2 and 20 h. Animals were euthanized after both time points and samples from different tissues were analyzed by gamma well counting. Whole-body imaging indicated a trend toward higher uptake in the brain in the ischemic group in comparison to control animals at both time points. Significant lung trapping occurred in all rats at 2 h but decreased at 20 h. Gamma well counting indicated higher activity in the ischemic hemisphere in comparison to the control group at 20 h. The authors estimated that 1 out of 10,000 cells migrated to the ischemic hemisphere. Strikingly, the uptake in the spleen increased between 2 and 20 h, while in the other organs it decreased. This finding could indicate that labeled human MSCs are sequestered in the spleen.

Arbab et al. [27] labeled human umbilical tissue-derived cells with $^{111}$In-oxine and injected them in the tail vein 48 h after transient MCAO in rats for 120 minutes. A total of $3 \times 10^6$ cells were used and SPECT imaging was performed at 0, 1, and 3 days. The authors found that the majority of the cells were retained in the lungs on day 0 (43.36±23.07%), while on days 1 and 3 this number declined to 8.81±7.75% and 4.01±4.52%, respectively. On the contrary, uptake in the lungs of rats that were given $^{111}$In-oxine alone persisted fairly unaltered from day 0 (18.38±5.45%) to day 1 (12.59±5.94%) and fell to 8.34±4.25% on day 3. They also reported that the ratio between the ischemic and nonischemic hemispheres was significantly higher ($P < 0.05$) on days 0, 1, and 3 in the animals that were given $^{111}$In-oxine-labeled cells (1.24±0.29, 1.63±0.39, 1.75±0.59, resp.) compared to the animals that were given only $^{111}$In-oxine (0.95±0.18, 1.13±0.22, 1.16±0.29, resp.).

Mitkari et al. [28] assessed the distribution of $^{111}$In-oxine labeled human BM-MSCs after 90 minutes of transient MCAO in rats and in sham operated animals. In addition to these two groups, they also analyzed the distribution of BM-MSCs treated with a proteolytic enzyme named Pronase (Roche, Mannheim, Germany), instead of trypsin, to transiently modify cell surface proteins. The rationale for the use of the proteolytic enzyme was that in previous unpublished data the authors saw a decrease in lung entrapment of
healthy mice after intravenous injection of unspecified cells. Approximately $0.5 \times 10^6$ (Pronase detached) to $1.1 \times 10^6$ cells (trypsin detached) were injected in the external carotid artery 24 h after the injury and SPECT/CT images were acquired at 30 minutes and 24 hours. After the last scan animals were euthanized and samples from the brain, liver, lungs, spleen, and kidneys were collected for gamma well counting. At 30 minutes after cell transplantation, there was high uptake in the brain in both MCAO and sham-operated animals. Nevertheless, the cells seemed to relocate to the liver and other organs at 24 h. Gamma well counting indicated higher uptake in the ischemic hemisphere in MCAO rats. There was no significant difference in the homing between Pronase and trypsin treated cells.

Goldmacher et al. [30] explored the homing of $^{111}$In-oxine labeled rat BM-MSCs in rats after 120 minutes of transient MCAO and in sham operated animals. A total of $5 \times 10^6$ cells were injected in the tail vein 24 h after the ischemia and whole-body planar images and brain pinhole images were acquired after 4, 20, 44, and 70 h. The authors described that the majority of intravenously infused cells remained in the lungs, while the uptake in the liver and spleen increased over time. Moreover, they described that in 44 and 70 h images higher activity was seen on the lesioned side of the head. However, no quantification was made in the images or by gamma well counting.

Manley et al. [32] tracked rat bone marrow dendritic cells (BM-DCs) labeled with $^{99m}$Tc-HMPAO transplanted after a transient MCAO for 60 minutes in rats. About $2 \times 10^6$ cells were injected in the carotid artery 3 h after the injury and SPECT images were performed at 5 to 20 minutes and 5 to 6 hours after transplantation. At 5 minutes after injection, 31% of the labeled BM-DCs homed to the lungs, 11% to the lesioned side of the head, and 26% to the liver, spleen, and gut. After 6 hours, 2–3% of the labeled BM-DCs remained in the lungs, 2-3% in the lesioned side of the head, and the remaining activity was found in the liver, spleen, and gut.

Wu et al. [34] analyzed the migration of rat BM-MSCs after 60 minutes of transient MCAO in rats. Cells were first transfected with the HSV1-TK reporter gene. Then, a total of $2 \times 10^6$ cells were injected in the carotid artery 3 h after the lesion and SPECT/CT images were acquired at 5 to 20 minutes and 5 to 6 hours later. Animals were euthanized and whole-body planar imaging was performed 1 h later. Liver and spleen were the organs with highest signal. Uptake in the head was similar to that of the other organs and soft tissues.

4.5. Global Brain Ischemia. In a paper from our group, Gubert et al. [29] carried out the transplantation of rat BM-MNCs labeled with $^{99m}$Tc in a rat model of global cerebral ischemia by bilateral common carotid artery ligation. About $2 \times 10^7$ cells were infused in the tail vein 24 h after the injury and whole-body planar imaging was performed 1 h later. Liver and spleen were the organs with highest signal. Uptake in the head was similar to that of the other organs and soft tissues.

Makela et al. [31] performed cell therapy using pig BM-MNCs labeled with $^{99m}$Tc-HMPAO in a model of global brain ischemia. In this model, pigs underwent transient carotid artery occlusion for 7 minutes. Approximately 6 to $20 \times 10^6$ cells were injected in the brachiocephalic trunk 24 h after the lesion and whole-body planar imaging and head SPECT/CT imaging was made 2, 4, 6, 12, and 24 h later. Animals were euthanized at the different time points and tissue samples were obtained for gamma well counting. The mean uptake for all time points was quantified in whole-body images and showed that the lungs had the highest signal (32.7%), followed by the liver (14.2%), spleen (7.3%), and kidneys (2.5%). There was no significant uptake in the brain in whole-body images or gamma well counting.

Ramos et al. [33], from our group, studied the migration of rat BM-MNCs after cell transplantation in rats with transient global ischemia and in sham-operated controls. The lesion was produced by permanent vertebral ligation and transient carotid artery occlusion for 17 minutes. Then, 24 or 72 h after the ischemic insult, 3 $\times 10^7$ cells were infused in the common carotid artery. Whole-body planar imaging and SPECT/CT were performed 2 h later. Subsequently, animals from the group that received cells at 72 h after the lesion...
were euthanized and their brains were isolated for gamma well counting. On planar and SPECT/CT images, activity was observed mainly in the site of injection, liver and spleen, with no significant activity in the brain. Gamma well counting indicated higher activity in the brains of ischemic animals, indicating that, although in very low amount, global ischemic lesion increased the homing of $^{99m}$Tc-BM-MNCs to the brain.

5. Published Clinical Trials

There have been 5 published articles in English concerning 2 different trials that used radiopharmaceuticals to track stem cell transplantation for neurological diseases, with a total of 13 treated patients (Table 2).

5.1. Acute Ischemic Stroke. Correa et al. [36] published a case report of a patient that received $^{99m}$Tc-HMPAO labeled BM-MNCs after an ischemic stroke in the posterior branch of the left middle cerebral artery. A total of $3 \times 10^7$ cells, 1% of them labeled, were injected in the left middle cerebral artery 9 days after the infarct. A whole-body planar scan and SPECT of the head were performed 8 h later. The SPECT scan showed homing of labeled cells to the anterior branch of the left middle cerebral artery, what probably occurred due to the persistent occlusion of the posterior branch. Whole-body images showed that uptake in the remaining organs occurred mainly to the liver and spleen. Nevertheless, no quantification of cell uptake in the different organs was made.

5.2. Subacute Ischemic Stroke. Our research group published a series of articles on a trial that used $^{99m}$Tc labeled cells for subacute middle cerebral artery stroke [37–40]. A total of 1 to $5 \times 10^8$ cells were infused in the middle cerebral artery or in the cephalic vein. Whole-body planar imaging was performed at 2 and 24 h and a SPECT of the head was carried out at 2 h after transplantation. Additionally, CT or MRI were performed before and up to 180 days after the therapy and the fusion of SPECT and CT or SPECT and MRI was performed. Seven patients were included in the intra-arterial group and 5 in the intravenous group, between 19 and 89 days after the stroke. The quantification of whole-body scans showed that the intra-arterial injection led to higher signal in the liver and spleen and lower signal in the lungs at 2 h when compared with the intravenous route. The analysis of SPECT images showed that the relative uptake in the ipsilateral hemisphere in comparison to the uptake in the brain was also higher in the intra-arterial group. At 24 h, the intravenous group had an increase in the percentage of homing to the liver and spleen and a decrease to the lungs when compared to 2 h scans. Nonetheless, the signal in the brain compared to the whole body continued being low and similar between both groups at 2 and 24 h.

6. Discussion

In addition to radiopharmaceutical cell labeling, there are other methods being investigated to track stem cells. For example, bioluminescence imaging has been successfully used to label cells in different models of stem cell therapies for neurological diseases [41–45]. However, it has narrow depth penetration (~1 cm) and cannot be used clinically [46]. Superparamagnetic iron oxide nanoparticles (SPIOs), initially developed for detection of hepatic lesions after intravenous injection, have also been used for cell labeling. In preclinical models, cell labeling with SPIOs allows tracking for days or weeks after injection with excellent resolution and anatomical correlation with MRI [47–49]. A few clinical trials have successfully labeled different stem cells with SPIOs for neurological diseases [50–53]. Nevertheless, SPIO labeling suffers from common limitations to other exogenous contrasts, such as dilution of the contrast media with cell division and the possibility that apoptotic stem cells may be phagocytized by macrophages, leading to signal that could be incorrectly associated with the cells. Furthermore, there are conflicting reports on the impact of nanoparticles in cellular events [54–57], and health authorities have not yet approved the use of SPIOs for cell labeling.

For these reasons, radiopharmaceutical cell tracking remains an important tool for evaluation of stem cell migration and homing. In addition to a more precise localization of the site of homing, the fusion of nuclear medicine images with CT or MRI allows evaluation of different aspects, such as (1) correlation of cell homing with positive morphological and functional effects, (2) evaluation of adverse reactions including brain hemorrhage or formation of tumors, and (3) the effect of different doses and routes of injection on cell migration and proliferation.

Studies using radiopharmaceuticals and other imaging modalities to track the fate of transplanted cells have given important clues about the mechanisms of action of cell-based therapies for neurological diseases. In many of these studies, the systemic delivery of different lineages of stem/progenitor cells exerted therapeutic effects by limiting tissue damage and/or by stimulating regeneration and plasticity of the diseased central nervous system (CNS) [58–60]. Although these effects have been associated with increased functional recovery, in most cases the number of transplanted cells that persisted at the lesion site was very low, as discussed above. These apparently paradoxical findings have shifted the attention from the controversial differentiation capacity of non-neural adult stem/progenitor cells (i.e., their potential to replace lost cells) to the mechanisms of intercellular communication between the transplanted and the host cells. Actually, even the therapeutic efficacy of cells committed to the neural fate, such as neural stem/progenitor cells, seems to be at least partially related to the secretion of innumerable neurotrophic, anti-inflammatory, and proangiogenic factors that contribute to CNS repair [61, 62]. Other potentially protective mechanisms that remain to be further characterized in the CNS are cell fusion [63] and mitochondrial transfer [64] between transplanted cells and host neurons.
| Study reference                                                                 | Radiopharmaceutical | Route                          | Cell type         | Type of lesion                  | Time from lesion | Number of treated patients (number of controls) | Number of cells injected | Infusion volume, rate, and duration | Imaging time points |
|--------------------------------------------------------------------------------|---------------------|--------------------------------|-------------------|---------------------------------|------------------|-----------------------------------------------|------------------------|-------------------------------------|-------------------|
| Correa et al., 2007 [36]                                                       | $^{99m}$Tc-HMPAO    | Middle cerebral artery         | BM-MNCs           | Middle cerebral artery ischemic stroke | 9 days           | 1 (no controls)                               | $3 \times 10^7$       | Not specified                       | 8 h                |
| Barbosa da Fonseca et al., 2009 [37], 2010 [38]; Battistella et al., 2011 [39]; Rosado-de-Castro et al., 2013 [40] | $^{99m}$Tc         | Middle cerebral artery or cephalic vein | BM-MNCs           | Middle cerebral artery ischemic stroke | 19–89 days       | 12 (no controls)                              | $1 \times 10^8$ to $5 \times 10^8$ | 10 mL in 10 min (1 mL/min)            | 2 and 24 h         |

$^{99m}$Tc: Technetium-$^{99m}$; $^{99m}$Tc-HMPAO: Technetium-$^{99m}$-hexamethylpropyleneamine oxime; BM-MNCs: bone marrow mononuclear cells.
Some stem/progenitor cells, such as BM-MSC, can also produce and secrete microvesicles and exosomes carrying proteins, bioactive lipids, microRNA, and mRNA. These exosomes could act through a paracrine mechanism or could be used for long-distance cellular communication when released in the systemic circulation [65]. For instance, a recent study has demonstrated that the systemic administration of purified exosomes from BM-MSC promoted functional recovery in a rodent model of stroke [66]. On the other hand, it has been shown that the exposure of BM-MSCs to ischemic brain extracts increased the levels of microRNA 133b in their exosomes. Interestingly, microRNA 133b was responsible for the increased neurite outgrowth observed in cultured neurons treated with these exosomes, suggesting that the ischemic brain could provide some cues that induce a proregenerative phenotype in BM-MSC [67].

These studies indicate that pharmacological and genetic manipulations aimed at stimulating the homing and engraftment of stem/progenitor cells in the CNS could enhance their therapeutic effects, by increasing the concentration of secreted factors at the lesion site, as well as by exposing the transplanted cells to local inflammatory cues. It is also necessary to improve the engraftment and long-term survival of neural stem cells (and their differentiated daughter cells) in some conditions where the main outcome depends on remyelination or on the replacement of lost cells, such as in congenital demyelinating diseases and in Parkinson’s disease, respectively. For this purpose it will be important to investigate the signaling mechanisms regulating the expression of chemokine receptors and adhesion molecules involved in the trafficking of these cells to inflammatory sites [68–70] and to understand how the diseased CNS environment modulate the phenotype and viability of the transplanted cells. For instance, BM-MSC can adopt different phenotypes when stimulated by proinflammatory cytokines, toll-like receptors agonists or when exposed to a hypoxic culture environment in vitro [71]. However, it is unclear how these factors could affect the secretome of transplanted stem/progenitor cells in vivo. Nuclear medicine imaging and other neuroimaging methods are therefore important tools to investigate all these questions.

Another line of evidence indicates that cell-based therapies could also exert their beneficial effects at long distances from the lesion site. Large numbers of injected cells migrate to the liver and spleen, where they could interact with inflammatory cells, such as splenocytes, invariant natural killer T cells, and tissue macrophages [72, 73]. Although still poorly understood, these interactions result in the modulation of systemic inflammation and seem to be necessary for the therapeutic effects following the administration of stem/progenitor cells in models of stroke, experimental autoimmune encephalomyelitis, and traumatic brain injury [74–85]. In the latter, intravenously transplanted bone marrow-derived progenitors promoted the preservation of splenic mass, by increasing the survival and the proliferation of splenocytes [81]. This treatment also stimulated the production of the anti-inflammatory cytokine IL-10 by splenocytes and increased the percentage of T regulatory cells in the spleen and blood, which are known for their immunosuppressive effects [80, 81].

As reviewed above, in many cases systemically transplanted stem/progenitor cells can be trapped in the lungs. The pulmonary passage may represent a barrier for the delivery of these cells into the CNS [86] but could also be necessary for the activation of some cell types, before their migration to the brain, as occurs with potentially autoaggressive T cells in experimental autoimmune encephalomyelitis [87]. Indeed, Lee et al. [88] observed the upregulation of the anti-inflammatory protein tumor necrosis factor-alpha stimulated gene/protein 6 (TGS-6) in intravenously infused MSC trapped in the lungs, in a mouse model of acute myocardial infarct. Their study indicated that MSC were activated in the lungs to secrete TGS-6, which in turn modulated the inflammatory response in the heart. Moreover, it has been shown that BM-MSC induced the production of the anti-inflammatory cytokine IL-10 by macrophages from septic lungs [89]. Finally, it remains to be investigated whether stem cells could exert a beneficial effect in the lungs in some neurological conditions like stroke, which is commonly associated with pneumonia [90, 91].

Another point that remains to be investigated is the combined use of endogenous labeling of other stem cell targets. For example, activated microglia play a central part in neuroinflammation and express a protein named the translocator protein 18 kDa (TSPO) [92–95]. Augmented TSPO expression has been demonstrated in different diseases such as Alzheimer’s disease, multiple sclerosis, encephalitis, and stroke [92–96]. PKII195 is a ligand of TSPO, and carbon-11 labeled PKII195 (¹¹C-PKII195) is a PET radiotracer that has been used for more than 20 years to quantify TSPO expression in the brain [92, 94]. Nevertheless, it has limitations such as high nonspecific binding and new tracers such as ¹¹C-PBR28 [97], 11C-DPA713 [98], and ¹³F-FEPPA [99] are under investigation.

In an example of combined use of labeling, Cicchetti et al. [100] labeled subventricular zone- (SVZ-) derived neural stem/progenitor cells with SPIOs to evaluate their migration with MRI and simultaneously utilized different radiotracers to analyze physiological aspects with PET. In their study, SVZ cells were transplanted into either the right rostral migratory stream (RMS) or striatum of adult Sprague-Dawley rats. While little migration of the cells transplanted into the striatum was seen after 3 weeks, neural stem/progenitor cells transplanted into the RMS migrated toward the olfactory bulb after 1 week. Interestingly, PET with ¹⁸F-FDG showed increased glucose metabolism and higher uptake of ¹¹C-CFT (dopamine transporter) and ¹¹C-raclopride (dopamine receptor type 2) in the striatum 3 months after the transplant. Moreover, transplanted cells did not lead to a significant local inflammatory response as evaluated by ¹¹C-PKII195 PET. Therefore, the combination of different imaging modalities allowed cell tracking in conjunction with the assessment of cell metabolism noninvasively. Taken together, such methods have the potential of answering important questions in the field of stem cell therapy.
7. Conclusion

Radiopharmaceutical cell labeling is a well-established technique that allowed tracking of stem cells in preclinical and clinical studies for neurological diseases. Intracerebral transplantation of radiopharmaceutically labeled stem cells led to accumulation in the site of injection in animal models of spinal cord injury. Similar findings occurred after intracerebral injection in animal models of traumatic brain injury and MCAO. In contrast, intravenous and intra-arterial injection led to small homing to the brain or spinal cord, and biodistribution was mainly to the liver, spleen, lungs, and kidneys, what also occurred in the clinical trials for stroke. Further studies are necessary to improve the understanding of the mechanisms behind cell homing and their correlation with the morphological and functional effects of stem cell therapies.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

Professors Bianca Gutfilen, Lea Mirian Barbosa da Fonseca, and Rosâlia Mendez-Otero receive Research Productivity Scholarships from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)/Ministry of Science, Technology and Innovation.). Professor Rosâlia Mendez-Otero also receives grants from CNPq, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ), CNPq, CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior)/Ministry of Education and from the Department of Science and Technology/(DECIT)/Ministry of Health. Dr Pedro Moreno Pimentel-Coelho is supported by a fellowship from Programa Ciência Sem Fronteiras-CAPES.

References

[1] F. Catalá-López, R. Génova-Maleras, E. Vieta, and R. Tabárés-Seisdedos, “The increasing burden of mental and neurological disorders,” European Neuropsychopharmacology, vol. 23, no. 11, pp. 1337–1339, 2008.

[2] C. J. Murray, T. Vos, R. Lozano et al., “Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010,” The Lancet, vol. 380, no. 9859, pp. 2197–2223, 2013.

[3] R. K. Burt, Y. Loh, W. Pearce et al., “Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases,” JAMA, vol. 299, no. 8, pp. 925–936, 2008.

[4] M. M. Lala, L. McIntyre, C. Pugliese et al., “Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials,” PLoS ONE, vol. 7, no. 10, Article ID e47559, 2012.

[5] C. J. Palestro, C. Love, and K. K. Bhargava, “Labeled leukocyte imaging: current status and future directions,” Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 53, no. 1, pp. 105–123, 2009.

[6] M. Roca, J. Martin-Comín, W. Becker et al., “A consensus protocol for white blood cells labelling with technetium-99m hexamethylpropylene amine oxime,” European Journal of Nuclear Medicine, vol. 25, no. 7, pp. 797–799, 1998.

[7] B. Gutfilen, S. A. Lopes De Souza, F. P. P. Martins, L. R. Cardoso, M. C. Pinheiro Pessoa, and L. M. B. Fonseca, “Use of 99mTc-monomononuclear leukocyte scintigraphy in nosocomial fever,” Acta Radiologica, vol. 47, no. 7, pp. 699–704, 2006.

[8] G. Mariani, L. Bruselli, T. Kuwert et al., “A review on the clinical uses of SPECT/CT,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 10, pp. 1599–1985, 2010.

[9] W. Brenner, A. Aicher, T. Eckey et al., “111In-labeled CD34+ hematopoietic progenitor cells in a rat myocardial infarction model,” Journal of Nuclear Medicine, vol. 45, no. 3, pp. 512–518, 2004.

[10] M.-F. Chen, C.-T. Lin, W.-C. Chen et al., “The sensitivity of human mesenchymal stem cells to ionizing radiation,” International Journal of Radiation Oncology Biology Physics, vol. 66, no. 1, pp. 244–253, 2006.

[11] A. Gholamrezaezhad, S. Mirpour, J. M. Ardekani et al., “Cytotoxicity of 111In-oxine on mesenchymal stem cells: a time-dependent adverse effect,” Nuclear Medicine Communications, vol. 30, no. 3, pp. 210–216, 2009.

[12] B. Nowak, C. Weber, A. Schober et al., “Indium-111 oxine labelling affects the cellular integrity of haematopoietic progenitor cells,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 5, pp. 715–721, 2007.

[13] G. J. Cook, S. Houston, R. Rubens, M. N. Maisey, and I. Fogelman, “Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions,” Journal of Clinical Oncology, vol. 16, no. 10, pp. 3375–3379, 1998.

[14] W. van der Bruggen, C. P. Bleeker-Rovers, O. C. Boerman, M. Gotthardt, and W. J. G. Oyen, “PET and SPECT in osteomyelitis and prosthetic bone and joint infections: a systematic review,” Seminars in Nuclear Medicine, vol. 40, no. 1, pp. 3–15, 2010.

[15] I. Buchmann, M. Henze, S. Engelbrecht et al., “Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 10, pp. 1617–1626, 2007.

[16] S. S. Yaghoubi, D. O. Campbell, C. G. Radu et al., “Positron emission tomography reporter genes and reporter probes: gene and cell therapy applications,” Theranostics, vol. 2, no. 4, pp. 374–401, 2012.

[17] H. Jiang, Z. Cheng, M. Tian, and H. Zhang, “In vivo imaging of embryonic stem cell therapy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 4, pp. 774–784, 2011.

[18] L. W. Dobrucki and A. J. Sinusas, “PET and SPECT in cardiovascular molecular imaging,” Nature Reviews Cardiology, vol. 7, no. 1, pp. 38–47, 2010.

[19] J. de Haro, M. Zurita, L. Ayllón, and J. Vaquero, “Detection of 111In-oxine-labeled bone marrow stromal cells after intravenous or intraslesional administration in chronic paraplegic rats,” Neuroscience Letters, vol. 377, no. 1, pp. 7–11, 2005.

[20] S. Mäkinen, T. Kekarainen, J. Nystedt et al., “Human umbilical cord blood cells do not improve sensorimotor or cognitive outcome following transient middle cerebral artery occlusion in rats,” Brain Research, vol. 1123, no. 1, pp. 207–215, 2006.

[21] R. S. Lappalainen, S. Narkilahti, T. Huhtala et al., “The SPECT imaging shows the accumulation of neural progenitor cells into
internal organs after systemic administration in middle cerebral artery occlusion rats," Neuroscience Letters, vol. 440, no. 3, pp. 246–250, 2008.

[22] W.-C. Lo, C.-H. Hsu, A. T. H. Wu et al., "A novel cell-based therapy for contusion spinal cord injury using GDNF-delivering NIH3T3 cells with dual reporter genes monitored by molecular imaging," Journal of Nuclear Medicine, vol. 49, no. 9, pp. 1512–1519, 2008.

[23] O. Detante, A. Woith, J. Dimastromatteo et al., “Intravenous administration of 99mTc-HMPAO-labeled human mesenchymal stem cells after stroke: in vivo imaging and biodistribution,” Cell Transplantation, vol. 18, no. 12, pp. 1369–1379, 2009.

[24] J.-K. Yoon, B.-N. Park, W.-Y. Shim, J. Y. Shin, G. Lee, and B. Mitkari, E. Kerkela, J. Nystedt et al., “Intra-arterial infusion of human bone marrow stem cells in acute brain trauma model,” Nuclear Medicine and Biology, vol. 37, no. 3, pp. 381–388, 2010.

[25] B.-N. Park, W. Shim, G. Lee et al., “Early distribution of intravenously injected mesenchymal stem cells in rats with acute brain trauma evaluated by 99mTc-HMPAO labeling.” Nuclear Medicine and Biology, vol. 38, no. 8, pp. 1175–1182, 2011.

[26] A. Vasconcelos-dos-Santos, P. H. Rosado-de-Castro, S. A. Lopes de Souza et al., “Intravenous and intra-arterial administration of bone marrow mononuclear cells after focal cerebral ischemia: is there a difference in biodistribution and efficacy?” Stem Cell Research, vol. 9, no. 1, pp. 1–8, 2012.

[27] A. S. Arbab, C. Thiffault, B. Navia et al., “Tracking of In-III-labeled human umbilical tissue-derived cells (hUUC) in a rat model of cerebral ischemia using SPECT imaging,” BMC Medical Imaging, vol. 12, p. 33, 2012.

[28] B. Mitkari, E. Kerkela, J. Nystedt et al., “Intra-arterial infusion of human bone marrow-derived mesenchymal stem cells results in transient localization in the brain after cerebral ischemia in rats,” Experimental Neurology, vol. 239, pp. 158–162, 2012.

[29] P. L. Correa, C. T. Mesquita, R. M. Felix et al., “Assessment of intra-arterial injected autologous bone marrow mononuclear cell distribution by radioactive labeling in acute ischemic stroke,” Clinical Nuclear Medicine, vol. 32, no. 11, pp. 839–841, 2007.

[30] L. M. Barbosa da Fonseca, V. Battistella, G. R. De Freitas et al., “Early tissue distribution of bone marrow mononuclear cells after intra-arterial delivery in a patient with chronic stroke,” Circulation, vol. 120, no. 6, pp. 539–541, 2009.

[31] L. M. Barbosa da Fonseca, B. Gutfilen, P. H. Rosado de Castro et al., “Migration and homing of bone-marrow mononuclear cells in chronic ischemic stroke after intra-arterial injection,” Experimental Neurology, vol. 221, no. 1, pp. 122–128, 2010.

[32] V. Battistella, G. R. De Freitas, L. M. Barbosa da Fonseca et al., “Safety of autologous bone marrow mononuclear cell transplantation in patients with nonacute ischemic stroke,” Regenerative Medicine, vol. 6, no. 1, pp. 45–52, 2011.

[33] P. H. Rosado-de-Castro, E. R. Schmidt, V. Battistella et al., “Biodistribution of bone marrow mononuclear cells after intra-arterial or intravenous transplantation in subacute stroke patients,” Regenerative Medicine, vol. 8, no. 2, pp. 145–155, 2013.

[34] M. M. Daadi, A. S. Davis, A. Arac et al., “Human neural stem cell grafts modify microglial response and enhance axonal sprouting in neonatal hypoxic-ischemic brain injury,” Stroke, vol. 41, no. 3, pp. 516–523, 2010.

[35] A. V. Pendharkar, J. Y. Chua, R. H. Andres et al., “Biodistribution of neural stem cells after intravascular therapy for Hypoxic-ischemia,” Stroke, vol. 41, no. 9, pp. 2064–2070, 2010.

[36] T. Sugiyama, S. Kuroda, T. Osanai et al., “Near-infrared fluorescence labeling allows noninvasive tracking of bone marrow stromal cells transplanted into rat infarct brain,” Neurosurgery, vol. 68, no. 4, pp. 1036–1047, 2011.

[37] A. M. Rondin, A. Cova, G. Levandis et al., “Noninvasive near-infrared live imaging of human adult mesenchymal stem cells transplanted in a rodent model of Parkinson’s disease,” International Journal of Nanomedicine, vol. 7, pp. 435–437, 2012.

[38] D.-E. Kim, K. Tsuji, Y. R. Kim et al., “Neural stem cell transplant survival in brains of mice: assessing the effect of immunity and ischemia by using real-time bioluminescent imaging,” Radiology, vol. 241, no. 3, pp. 822–830, 2006.

[39] A. S. Arbab, B. Janic, J. Haller, E. Pawelczyk, W. Liu, and J. A. Frank, “In vivo cellular imaging for translational medical research,” Current Medical Imaging Reviews, vol. 5, no. 1, pp. 19–38, 2009.

[40] M. D. Budde and J. A. Frank, “Magnetic tagging of therapeutic cells for MRI,” Journal of Nuclear Medicine, vol. 50, no. 2, pp. 171–174, 2009.

[41] Z. Lee, J. E. Dennis, and S. L. Gerson, “Imaging stem cell implant for cellular-based therapies,” Experimental Biology and Medicine, vol. 233, no. 8, pp. 930–940, 2008.

[42] L. Moraes, A. Vasconcelos-dos-Santos, F. C. Santana et al., “Neuroprotective effects and magnetic resonance imaging of mesenchymal stem cells labeled with SPION in a rat model of Huntington’s disease,” Stem Cell Research, vol. 9, no. 2, pp. 143–155, 2012.

[43] F. Callera and C. M. T. P. De Melo, “Magnetic resonance tracking of magnetically labeled autologous bone marrow CD34+ cells transplanted into the spinal cord via lumbar puncture technique in patients with chronic spinal cord injury: CD34+ cells migration into the injured site,” Stem Cells and Development, vol. 16, no. 3, pp. 461–466, 2007.
[51] D. Karussis, C. Karageorgiou, A. Vaknin-Dembinsky et al., "Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis," *Archives of Neurology*, vol. 67, no. 10, pp. 1187–1190, 2014.

[52] J. Zhu, L. Zhou, and F. Xing Wu, "Tracking neural stem cells in patients with brain trauma," *The New England Journal of Medicine*, vol. 355, no. 22, pp. 2376–2378, 2006.

[53] T. J. Englund, M. Abaei, D. P. Auer et al., "Granulocyte-colony stimulating factor for mobilizing bone marrow stem cells in subacute stroke: the stem cell trial of recovery enhancement after stroke 2 randomized controlled trial," *Stroke*, vol. 43, no. 2, pp. 405–411, 2012.

[54] E. Farrell, P. Wielopolski, P. Pavljasevic et al., "Effects of iron oxide incorporation for long term cell tracking on MSC differentiation in vitro and in vivo," *Biochemical and Biophysical Research Communications*, vol. 369, no. 4, pp. 1076–1081, 2008.

[55] H. S. Kim, S. Y. Oh, H. J. Joo, K.-R. Son, I.-C. Song, and W. K. Moon, "The effects of clinically used MRI contrast agents on the biological properties of human mesenchymal stem cells," *NMR in Biomedicine*, vol. 23, no. 5, pp. 514–522, 2010.

[56] Jasmin, A. L. Torres, L. Jelicks, A. C. de Carvalho, D. C. Spray, and R. Mendez-Otero, "Labeling stem cells with superparamagnetic iron oxide nanoparticles: analysis of the labeling efficacy by microscopy and magnetic resonance imaging," *Methods in Molecular Biology*, vol. 906, pp. 239–252, 2012.

[57] J. Jasmin, A. L. M. Torres, H. M. P. Nunes et al., "Optimized labeling of bone marrow mesenchymal cells with superparamagnetic iron oxide nanoparticles and in vivo visualization by magnetic resonance imaging," *Journal of Nanobiotechnology*, vol. 9, article 4, 2011.

[58] P. M. Pimentel-Coelho and R. Mendez-Otero, "Cell therapy for neonatal hypoxic-ischemic encephalopathy," *Stem Cells and Development*, vol. 19, no. 3, pp. 299–309, 2010.

[59] P. H. Rosado-de-Castro, P. M. Pimentel-Coelho, L. M. Barbosa da Fonseca et al., "The rise of cell therapy trials for stroke: review of published and registered studies," *Stem Cells and Development*, vol. 22, no. 15, pp. 2095–2113, 2013.

[60] P. M. Pimentel-Coelho, P. H. Rosado-de-Castro, L. M. Barbosa da Fonseca et al., "Umbilical cord blood mononuclear cell transplantation for neonatal hypoxic-ischemic encephalopathy," *Pediatric Research*, vol. 71, no. 4, part 2, pp. 464–473, 2012.

[61] M. Bacigaluppi, S. Pluchino, L. P. Jametti et al., "Delayed postschaemic neuroprotection following systemic neural stem cell transplantation involves multiple mechanisms," *Brain*, vol. 132, no. 8, pp. 2239–2251, 2009.

[62] N. Horie, M. P. Pereira, K. Nizuma et al., "Transplanted stem cell-secreted vascular endothelial growth factor effects poststroke recovery, inflammation, and vascular repair," *Stem Cells*, vol. 29, no. 2, pp. 274–285, 2011.

[63] E. Brilli, E. Reitano, L. Conti et al., "Neural stem cells engrafted in the adult brain fuse with endogenous neurons," *Stem Cells and Development*, vol. 22, no. 4, pp. 538–547, 2013.

[64] M. N. Islam, S. R. Das, M. T. Emin et al., "Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury," *Nature Medicine*, vol. 18, no. 5, pp. 759–765, 2012.

[65] F. T. Borges, L. A. Reis, and N. Schor, "Extracellular vesicles: structure, function, and potential clinical uses in renal diseases," *Brazilian Journal of Medical and Biological Research*, vol. 46, no. 10, pp. 824–830, 2013.

[66] H. Xin, Y. Li, Y. Cui et al., "Systemic administration of exosomes released from mesenchymal stromal cells promote functional recovery and neurovascular plasticity after stroke in rats," *Journal of Cerebral Blood Flow & Metabolism*, vol. 33, no. 11, pp. 1711–1715, 2013.

[67] H. Xin, Y. Li, Z. Liu et al., "MiR-133b promotes neural plasticity and functional recovery after treatment of stroke with multipotent mesenchymal stromal cells in rats via transfer of exosome-enriched extracellular particles," *Stem Cells*, vol. 31, no. 12, pp. 2737–2746, 2013.

[68] J. Imitola, T. Chitnis, and S. J. Khoury, "Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implications for future therapies," *Archives of Neurology*, vol. 63, no. 1, pp. 25–33, 2006.

[69] Y. Wang, Y. Deng, and G.-Q. Zhou, "SDF-1α/CXCR4-mediated migration of systemically transplanted bone marrow stromal cells towards ischemic brain lesion in a rat model," *Brain Research*, vol. 1195, pp. 104–112, 2008.

[70] R. H. Andres, R. Choi, A. V. Pendharkar et al., "The CCR2/CCL2 interaction mediates the transendothelial recruitment of intravascularly delivered neural stem cells to the ischemic brain," *Stroke*, vol. 42, no. 10, pp. 2923–2931, 2011.

[71] S. H. Ranganath, O. Levy, M. S. Inamdar, and J. M. Karp, "Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease," *Cell Stem Cell*, vol. 10, no. 3, pp. 244–258, 2012.

[72] F. K. Swirski, M. Nahrendorf, M. Etzrodt et al., "Identification of splenic reservoir monocytes and their deployment to inflammatory sites," *Science*, vol. 325, no. 5940, pp. 612–616, 2009.

[73] C. H. Y. Wong, C. N. Jenne, W.-Y. Lee, C. Léger, and P. Kubes, "Functional innervation of hepatic inKNT cells is immunosuppressive following stroke," *Science*, vol. 334, no. 6052, pp. 101–105, 2011.

[74] M. Vendrame, C. Gemma, K. R. Pennypacker et al., "Cord blood rescues stroke-induced changes in splenocyte phenotype and function," *Experimental Neurology*, vol. 199, no. 1, pp. 191–200, 2006.

[75] S.-T. Lee, K. Chu, K.-H. Jung et al., "Anti-inflammatory mechanism of intravascular neural stem cell transplantation in haemorrhagic stroke," *Brain*, vol. 131, no. 3, pp. 616–629, 2008.

[76] S. Schwarting, S. Litwak, W. Hao, M. Bähr, J. Weise, and H. Neumann, "Hematopoietic stem cells reduce postschismic inflammation and ameliorate ischemic brain injury," *Stroke*, vol. 39, no. 10, pp. 2867–2875, 2008.

[77] Z. Lu, X. Hu, C. Zhu, D. Wang, X. Zheng, and Q. Liu, "Overexpression of CNTF in mesenchymal stem cells reduces demyelination and induces clinical recovery in experimental autoimmune encephalomyelitis mice," *Journal of Neuroimmunology*, vol. 206, no. 1-2, pp. 58–69, 2009.

[78] B. Yang, R. Strong, S. Sharma et al., "Therapeutic time window and dose response of autologous bone marrow mononuclear cells for ischemic stroke," *Journal of Neuroscience Research*, vol. 89, no. 6, pp. 833–839, 2011.

[79] S. I. Savitz. "Stem cells and stroke: are we further away than anyone is willing to admit?" *International Journal of Stroke*, vol. 7, no. 1, pp. 34–35, 2012.

[80] P. A. Walker, S. S. Bedi, S. K. Shah et al., "Intravenous multipotent adult progenitor cell therapy after traumatic brain injury: modulation of the resident microglia population," *Journal of Neuroinflammation*, vol. 9, p. 228, 2012.

[81] P. A. Walker, S. K. Shah, F. Jimenez et al., "Intravenous multipotent adult progenitor cell therapy for traumatic brain
injury: preserving the blood brain barrier via an interaction with splenocytes,” Experimental Neurology, vol. 225, no. 2, pp. 341–352, 2010.

[82] C. V. Borlongan, L. E. Glover, P. R. Sanberg et al., “Permeating the blood brain barrier and abrogating the inflammation in stroke: implications for stroke therapy,” Current Pharmaceutical Design, vol. 18, no. 25, pp. 3670–3676, 2012.

[83] C. V. Borlongan, M. Hadman, C. D. Sanberg, and P. R. Sanberg, “Central nervous system entry of peripherally injected umbilical cord blood cells is not required for neuroprotection in stroke,” Stroke, vol. 35, no. 10, pp. 2385–2389, 2004.

[84] D. C. Hess and C. V. Borlongan, “Cell-based therapy in ischemic stroke,” Expert Review of Neurotherapeutics, vol. 8, no. 8, pp. 1193–1201, 2008.

[85] D. C. Hess and C. V. Borlongan, “Stem cells and neurological diseases,” Cell Proliferation, vol. 41, no. 1, pp. 94–114, 2008.

[86] U. M. Fischer, M. T. Harting, F. Jimenez et al., “Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect,” Stem Cells and Development, vol. 18, no. 5, pp. 683–691, 2009.

[87] F. Odoardi, C. Sie, K. Streyl et al., “T cells become licensed in the lung to enter the central nervous system,” Nature, vol. 488, no. 7413, pp. 675–679, 2012.

[88] R. H. Lee, A. A. Pulin, M. J. Seo et al., “Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6,” Cell Stem Cell, vol. 5, no. 1, pp. 54–63, 2009.

[89] K. Németh, A. Leelahavanichkul, P. S. T. Yuen et al., “Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production,” Nature Medicine, vol. 15, no. 1, pp. 42–49, 2009.

[90] H. Kamel and C. Iadecola, “Brain-immune interactions and ischemic stroke: clinical implications,” Archives of Neurology, vol. 69, no. 5, pp. 576–581, 2012.

[91] J. W. Lee, A. Krasnodembskaya, D. H. McKenna et al., “Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria,” American Journal of Respiratory and Critical Care Medicine, vol. 187, no. 7, pp. 751–760, 2013.

[92] J. H. Ko, Y. Koshimori, R. Mizrahi et al., “Voxel-based imaging of translocator protein 18 kDa (TSPO) in high-resolution PET,” Journal of Cerebral Blood Flow and Metabolism, vol. 33, no. 3, pp. 348–350, 2013.

[93] M. Cosenza-Nashat, M.-L. Zhao, H.-S. Suh et al., “Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain,” Neuropathology and Applied Neurobiology, vol. 35, no. 3, pp. 306–328, 2009.

[94] J. Hirvonen, A. Roivainen, J. Virta, S. Helin, K. Nägren, and J. O. Rinne, “Human biodistribution and radiation dosimetry of [11C]-R-PK11195, the prototypic PET ligand to image inflammation,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 3, pp. 606–612, 2010.

[95] V. Papadopoulos, M. Baraldi, T. R. Guilarte et al., “Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function,” Trends in Pharmacological Sciences, vol. 27, no. 8, pp. 402–409, 2006.

[96] A. Cagnin, M. Kassiou, S. R. Meikle, and R. B. Banati, “Positron emission tomography imaging of neuroinflammation,” Neuroradiology, vol. 4, no. 3, pp. 443–452, 2007.